Digital Tools-Regulatory Considerations for Application in Clinical Trials.

Area of Science:

• Pharmaceutical industry
• Digital health technology (DHT)
• Regulatory science

Background:

• The pharmaceutical sector increasingly adopts digital health technology (DHT) for drug development and commercialization.
• Regulatory bodies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) support technological advancements.
• Differing regulatory landscapes, such as the US Cures Act and the EU's Medical Device Regulation, present unique challenges and opportunities for digital health innovation.

Purpose of the Study:

• To analyze the regulatory frameworks of the FDA and EMA concerning digital tools in clinical drug development.
• To propose strategic approaches for global pharmaceutical companies navigating these regulations.
• To identify pathways for ensuring digital tools meet safety, performance, and data integrity standards.

Main Methods:

• Comparative analysis of the US FDA and EU EMA regulatory requirements for digital health technology.
• Evaluation of validation and qualification processes for digital tools in drug development.
• Assessment of GxP, data privacy, and cybersecurity compliance for DHTs.

Main Results:

• Digital tools must be fit-for-purpose, meeting basic safety and performance requirements regardless of Medical Device status.
• Both regions require adherence to quality systems, surveillance, GxP, data privacy, and cybersecurity regulations.
• There is an overlap in technical and clinical validation, crucial for qualifying drug development tools and ensuring reliable data.

Conclusions:

• Pharmaceutical companies should consider using approved solutions or qualifying drug development tools early and in parallel with clinical development.
• Early engagement with regulatory agencies (FDA, EMA/CA) is recommended to define evidentiary standards and regulatory pathways.
• Harmonization of disparate US and EU regulations and further development of the EU landscape could significantly boost the use of digital tools in clinical trials.